Neurol. praxi. 2019;20(1):25-27 | DOI: 10.36290/neu.2019.086

When to close patent foramen ovale?

MUDr. Martin ©rámek
Komplexní cerebrovaskulární centrum Ústavu klinických neurooborů, Ústřední vojenská nemocnice – Vojenská fakultní nemocnice Praha
Neurologická klinika 2. LF UK a FN Motol, Praha

Closure of patent foramen ovale (PFO) is effective secondary prevention after ischemic stroke proven by randomised clinical
trials. The key is selection of the right patient by excluding usual cerebrovascular risc factors (atherosclerosis, atrial fibrilation,…).
A suitable tool to identify the proper patient is the ROPE score (risc of paradoxial embolization). Closure of PFO is not indicated
either in patients with migraine or in most divers with identified PFO.

Keywords: patent foramen ovale, ischaemic stroke, cryptogenic, migraine with aura, decompression sickness

Published: March 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©rámek M. When to close patent foramen ovale? Neurol. praxi. 2019;20(1):25-27. doi: 10.36290/neu.2019.086.
Download citation

References

  1. Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Wolf ME, Hennerici MG. The ASCOD phenotyping of ischemic stroke (Updated ASCO Phenotyping). 1. Cerebrovasc Dis. 2013; 36(1): 1-5. Go to original source...
  2. Arauz A, Murillo L, Márquez JM, Tamayo A, Cantú C, Roldan FJ, Vargas-Barrón J, Barinagarrementeria F. Long-term risk of recurrent stroke in young cryptogenic stroke patients with and without patent foramen ovale. Int J Stroke 2012; 7(8): 631-634. Go to original source... Go to PubMed...
  3. Arquizan C, Costel J, Touboul PJ, et al. Is Patent foramen ovale a family trait? Stroke 2001; 32: 1563-1566. Go to original source... Go to PubMed...
  4. Cohnheim J. Thrombose und Embolie. In: Vorlesung űber allgemeine Pathologie, Vol. 1. Berlin: August Hirschwald Verlag 1877: 134.
  5. Del Sette M, Angeli S, Leandri M, Ferriero G, Bruzzone GL, Finocchi C, Gandolfo C. Migraine with aura and right-to-left shunt on transcranial Doppler: A case-control study. Cerebrovasc Dis 1998; 8: 327-330. Go to original source... Go to PubMed...
  6. Dowson A, Mullen MJ, Peatfield R, Muir K, Khan AA, Wells C, Lipscombe SL, Rees T, De Giovanni JV, Morrison WL, Hildick-Smith D, Elrington G, Hillis WS, Malik IS, Rickards A. Migraine Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation 2008; 117(11): 1397-1404. Go to original source...
  7. Kent DM, Ruthazer R, Wimar C, Mas JL, Serena J, Homma S, Di Angelantonio E, Di Tullio MR, Lutz JS, Elkind MS, Griffith J, Jaigobin C, Mattle HP, Michel P, Mono ML, Nedeltchev K, Pepetti F, Thaler DF. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology 2013; 81(7): 619-625. Go to original source... Go to PubMed...
  8. Lairez O, Cournot M, Minville V, Roncalli J, Austruy J, Elbaz M, Galinier M, Carrie D, Risk of neurological decompression sickness in the diver with a right-to-left shunt: literature review and meta-analysis. Clin J Sport Med 2009; 19: 231-235. Go to original source... Go to PubMed...
  9. Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, Coste J; Patent Foramen Ovale and Atrial Septal Aneurysm Study Group. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001; 345: 1740-1746. Go to original source...
  10. Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, Arquizan C, Béjot Y, Vuillier F, Detante O, Guidoux C, Canaple S, Vaduva C, Dequatre-Ponchelle N, Sibon I, Garnier P, Ferrier A, Timsit S, Robinet-Borgomano E, Sablot D, Lacour JC, Zuber M, Favrole P, Pinel JF, Apoil M, Reiner P, Lefebvre C, Guérin P, Piot C, Rossi R, Dubois-Randé JL, Eicher JC, Meneveau N, Lusson JR, Bertrand B, Schleich JM, Godart F, Thambo JB, Leborgne L, Michel P, Pierard L, Turc G, Barthelet M, Charles-Nelson A, Weimar C, Moulin T, Juliard JM, Chatellier G. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017; 377: 1011-1021. Go to original source...
  11. Mattle HP, Evers S, Hildick-Smith D, Becker WJ, Baumgartner H, Chataway J, Gawel M, Göbel H, Heinze A, Horlick E, Malik I, Ray S, Zermansky A, Findling O, Windecker S, Meier B. Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial. Eur Heart J. 2016; 37(26): 2029-2036. Go to original source... Go to PubMed...
  12. Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, Tirschwell DL. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017; 377: 1022-1032. Go to original source...
  13. S?ndergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, Settergren M, Sjöstrand C, Roine RO, Hildick-Smith D, Spence JD, Thomassen L. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017; 377: 1033-1042. Go to original source...
  14. Tobis JM, Charles A, Silberstein SD, Sorensen S, Maini B, Horwitz PA, Gurley JC. Percutaneous closure of patent foramen ovale in patients with migraine: The PREMIUM Trial. J Am Coll Cardiol. 2017; 70(22): 2766-2774. Go to original source...
  15. Wilmshurst PT, Ellis BG, Jenkins BS. Paradoxical gas embolism in a scuba diver with an atrial septal defect. Brit Med J 1986; 293: 1277. Go to original source...
  16. Wilmshurst PT, Nightingale S, Walsh KP et al. Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lancet 2000; 356: 1648-1651. Go to original source...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.